Surgical therapy for early hepatocellular carcinoma in the modern era: A 10-Year SEER-medicare analysis

Annals of Surgery

Volumn 258, Issue 6, 2013, Pages 1022-1027

  Nathan, Hari ^a   Hyder, Omar ^a   Mayo, Skye C ^a   Hirose, Kenzo ^a   Wolfgang, Christopher L ^a   Choti, Michael A ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hepatocellular carcinoma; SEER Medicare; surgery; therapy

Indexed keywords

AGED; ALCOHOL LIVER DISEASE; ARTICLE; ARTIFICIAL EMBOLISM; CANCER REGISTRY; CHRONIC HEPATITIS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; EARLY CANCER; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; INCIDENCE; INCOME; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICARE; METASTASIS; PORTAL HYPERTENSION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; URBAN POPULATION; VIRUS HEPATITIS;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MEDICARE; RETROSPECTIVE STUDIES; SEER PROGRAM; TIME FACTORS; UNITED STATES;

EID: 84888138358     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31827da749     Document Type: Article

References (29)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
2. Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2011;20:2362-2368.
3. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(suppl 1):S27-S34.
4. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
5. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
6. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19:311-322.
7. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-1440.
8. Nathan H, Schulick RD, Choti MA, et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799-805.
9. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328.
10. Cho YK, Kim JK, Kim MY, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453-459.
11. Nathan H, Segev DL, Mayo SC, et al. National trends in surgical procedures for hepatocellular carcinoma: 1998-2008. Cancer. 2012;118:1838-1844.
12. El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158-166.
13. Shah SA, Smith JK, Li Y, et al. Underutilization of therapy for hepatocellular carcinoma in the Medicare population. Cancer. 2011;117:1019-1026.
14. Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at aWestern center. Ann Surg. 1999;229:790-799; discussion 799-800.
15. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397-406; discussion 406-407.
16. Nathan H, Pawlik TM. Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol. 2008;15:415-423.
17. Fritz AG. International Classification of Diseases for Oncology: ICD-O. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
18. Simons JP, Ng SC, McDade TP, et al. Progress for resectable pancreatic cancer?: a population-based assessment of US practices. Cancer. 2010;116:1681-1690.
19. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
20. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
21. vanWalraven C, Austin PC, Jennings A, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47:626-633.
22. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4:87-90.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. Akaike H. New look at statistical-model identification. IEEE Trans Automatic Control. 1974;Ac19:716-723.
25. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-422.
26. Sonnenday CJ, Dimick JB, Schulick RD, et al. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg. 2007;11:1636-1646; discussion 1646.
27. Cooper GS, Virnig B, Klabunde CN, et al. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(suppl):IV-43-48.
28. Baldwin LM, Klabunde CN,Green P, et al. In search of the perfect comorbidity measure for use with administrative claims data: does it exist? Med Care. 2006;44:745-753.
29. Nathan H, Bridges JF, Schulick RD, et al. Understanding surgical decision making in early hepatocellular carcinoma. J Clin Oncol. 2011;29:619-625.